← Back

Guangzhou LBP Medicine Science & Technology Co Ltd

Guangzhou LBP Medicine Science & Technology Co., Ltd. researches, develops, and produces pathological diagnosis products in China and internationally. Its offerings include pathological diagnostic reagents and ancillary equipment such as liquid-based cytology products, polymerase chain reaction products, fluorescence in situ hybridization products, digital pathology products, and immunohistochemistry products. The company was founded in 2005 and is based in Guangzhou, China.

Price · split & dividend adjusted
News & notes moving 688393.CG
688393.CG

Anbiping Releases 2026 Interim Report, Net Profit of 764,900 Yuan

Anbiping released its 2026 interim report on August 28, 2026. During the reporting period, the company's total operating revenue was 172 million yuan, and net profit attributable to the parent company was 764,900 yuan. Net cash inflow from operating activities was 3.2979 million yuan, a decrease of 15.7147 million yuan compared with the same period last year, down 82.65 percent year on year. The company's latest asset-liability ratio was 9.32 percent, gross margin was 65.94 percent, ROE was 0.07 percent, and diluted earnings per share was 0.01 yuan. The number of shareholders was 7,700, and the top ten shareholders held 49.14 percent of the total share capital.
688393.CG
Jiemian·22dRead more →
688393.CG▲

Anbiping's First-Half Non-Recurring Loss Narrows to 680,000 Yuan

Anbiping released its 2026 half-year report. First-half operating revenue was 172 million yuan, up 7.6 percent year on year. Net profit attributable to the parent turned from loss to profit, reaching 760,000 yuan. The non-recurring net loss attributable to the parent narrowed to 680,000 yuan, compared with a loss of 14.71 million yuan in the same period last year. In the second quarter, the company's operating revenue was 91.96 million yuan, up 5.9 percent year on year. Net profit attributable to the parent turned positive at 2.6 million yuan, and non-recurring net profit attributable to the parent turned positive at 2.07 million yuan. As of the end of the second quarter, total assets were 1.25 billion yuan, down 2.9 percent from the end of the previous year, and net assets attributable to the parent were 1.137 billion yuan, down 4.0 percent. The company's main business covers the full industry chain of hospital pathology departments. It added 47 medical device registration certificates and 47 overseas certifications. Revenue from pathology department co-construction business was 14.06 million yuan, up 20.28 percent year on year.
688393.CG ▲
财中社·23dRead more →
© 2026 MarketDXAsset